Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,506Revenue $M135Net Margin (%)-127.4Altman Z-Score-1.7
Enterprise Value $M1,605EPS $-0.9Operating Margin %-120.7Piotroski F-Score5
P/E(ttm)--Beneish M-Score-2.3Pre-tax Margin (%)-126.7Higher ROA y-yY
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio3.3Cash flow > EarningsY
Price/Sales11.15-y EBITDA Growth Rate %--Current Ratio3.3Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-31.8Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-277.9Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M189ROIC % (ttm)-154.9Gross Margin Increase y-yY

Gurus Latest Trades with ARIA

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ARIAJoel Greenblatt 2015-06-30 Sold Out $7.9 - $9.71
($8.83)
$ 7.97-10%Sold Out0
ARIAMichael Price 2015-03-31 Buy 0.6%$6.1 - $8.97
($7.39)
$ 7.978%New holding550,000
ARIAJoel Greenblatt 2015-03-31 Buy $6.1 - $8.97
($7.39)
$ 7.978%New holding16,344
ARIAGeorge Soros 2014-12-31 Sold Out -0.01%$5.02 - $7.46
($6.28)
$ 7.9727%Sold Out0
ARIAGeorge Soros 2014-09-30 Reduce-0.04%$5.01 - $6.5
($5.84)
$ 7.9736%Reduce 85.00%150,000
ARIAGeorge Soros 2014-06-30 Add0.02%$6.3 - $8.52
($6.89)
$ 7.9716%Add 100.00%1,000,000
ARIAGeorge Soros 2014-03-31 Reduce-0.08%$6.46 - $8.99
($7.75)
$ 7.973%Reduce 74.36%500,000
ARIAGeorge Soros 2013-12-31 Buy 0.11%$2.2 - $18.8
($5.16)
$ 7.9754%New holding1,950,000
ARIAGeorge Soros 2012-06-30 Sold Out -0.15%$14.6 - $17.82
($16.35)
$ 7.97-51%Sold Out0
ARIAGeorge Soros 2012-03-31 Buy 0.15%$12.73 - $16.32
($13.74)
$ 7.97-42%New holding635,000
ARIAGeorge Soros 2011-12-31 Sold Out -0.07%$8.03 - $12.5
($10.96)
$ 7.97-27%Sold Out0
ARIAGeorge Soros 2011-09-30 Buy 0.07%$7.63 - $13.34
($10.54)
$ 7.97-24%New holding496,847
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ARIA is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


ARIA: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Cantor Maria ESVP, Corporate Affairs 2015-09-01Sell2,696$9.11-12.51view
FITZGERALD EDWARD MExecutive VP, CFO 2015-08-28Sell32,858$10-20.3view
Cantor Maria ESVP, Corporate Affairs 2015-08-28Sell1,268$10-20.3view
CLACKSON TIMOTHY PPresident, R&D, CSO 2015-07-16Sell7,000$8.54-6.67view
Duvall Martin JEVP, CCO 2015-07-16Sell1,400$8.54-6.67view
FITZGERALD EDWARD MExecutive VP, CFO 2015-07-16Sell7,000$8.54-6.67view
Bollag Daniel MSr. VP, Reg. Affairs & Quality 2015-07-16Sell4,000$8.54-6.67view
Cantor Maria ESVP, Corporate Affairs 2015-07-16Sell4,000$8.54-6.67view
BERSTEIN DAVID LSVP, Chief IP Counsel 2015-07-16Sell4,000$8.54-6.67view
Haluska FrankSVP, Clinical R&D, CMO 2015-07-16Sell4,400$8.54-6.67view

Quarterly/Annual Reports about ARIA:

News about ARIA:

Articles On GuruFocus.com
Michael Price Invests in 11 Companies in First Quarter May 19 2015 
Sarah Ketterer of Causeway Capital's Answers to GuruFocus Q&A Apr 07 2014 
Weekly CEO Sells Highlight: U.S. Bancorp, Restoration Hardware Holdings Inc, Ariad Pharmaceuticals, Jul 20 2013 
Daniel Loeb's Top Three Increases of the First Quarter May 24 2013 
comment on ARIA Mar 15 2013 
comment on ARIA Mar 15 2013 
comment on ARIA May 16 2012 
Weekly CFO Sales Highlight: WWWW, FIO, CRIS, ARIA, VOG, APKT Apr 22 2012 
3 Biotech Stocks To Consider Buying Right Now Jan 10 2012 
ARIAD Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 15 2011 

More From Other Websites
Mid-Morning Market Update: Markets Open Lower; BlackBerry To Acquire Good Technology For $425M Sep 04 2015
ARIAD Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner – Sept 3, 2015 Sep 03 2015
ETF’s with exposure to ARIAD Pharmaceuticals, Inc. Sep 03 2015
Hedge Funds Like Ariad Pharmaceuticals, Inc. (ARIA) Despite the Failed Deal Sep 03 2015
The Zacks Analyst Blog Highlights: Amgen, ARIAD, Celgene, Amicus and Alnylam Sep 03 2015
Overheard: Baxalta Shows Rare Deal Discipline Sep 02 2015
Word is the Ariad-Baxalta deal is dead. Here’s what we learned. Sep 02 2015
Baxalta Said to Quit Ariad Takeover Talks Sep 02 2015
Baxalta Said to Abandon Takeover Talks With Drugmaker Ariad Sep 02 2015
Biotech Stock Roundup: Amgen in the News, ARIAD a Takeover Target? Sep 02 2015
​Ariad is at the bottom of a big biotech food chain, at least for now Sep 01 2015
Mid-Afternoon Market Update: NASDAQ Down 1.3%; Medicines Company Shares Gain Following Announcement... Aug 31 2015
Ariad and Baxalta stay mum on merger reports, but speculation abounds Aug 31 2015
3 High-Volume Stocks to Trade Now (or Not) Aug 31 2015
Mid-Day Market Update: Crude Oil Surges 5.5%; ConforMIS Shares Tumble Aug 31 2015
ARIAD Skyrockets More than 40% Following Buyout Rumors Aug 31 2015
Ariad Pharmaceuticals (ARIA) Jumps: Stock Moves Up 41.7% Aug 31 2015
Baxalta makes $2bn move for rival after shunning Shire Aug 28 2015
The Top 3 Medtech Buyout Rumors This Week Aug 28 2015

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK